Frank D’Amelio is the former Executive Vice President & Chief Financial Officer at Pfizer Inc, responsible for all corporate finance functions including audit, treasury, tax, investor relations, insurance, operations planning and analysis, corporate controllership, and business finance and analytics.  From 2019 through 2021, Frank was the Chief Financial Officer & Executive Vice President, Global Supply responsible for Pfizer’s worldwide global supply chain.  This included the manufacture and distribution of the COVID vaccine. More than 3B doses of the COVID vaccine were made in the first year of production.

At Pfizer, Frank has led the acquisition and integration of Wyeth Pharmaceuticals, King Pharmaceuticals, Hospira Inc., Anacor Pharmaceuticals, Inc., Medivation, Inc. and Array, as well as the spin-off of Pfizer’s animal health business, Zoetis, the sale of its nutrition business to Nestle and its Capsugel business to KKR, the formation of the Consumer JV with GSK and the formation of Viatris with Mylan.

During Frank’s tenure as the Pfizer CFO, Pfizer’s market cap has increased by $165B. Including the Zoetis spin-off, market cap increased by approximately $250B. Further, Frank has completed business development transactions totaling approximately $200B.

Before joining Pfizer in September 2007, Frank was Senior Executive Vice President of Integration and Chief Administrative Office of Alcatel-Lucent, responsible for the integration of the Alcatel-Lucent merger as well as procurement, real estate, IT and supply chain.

Prior to the merger of Alcatel and Lucent Technologies in 2006, Frank was the Chief Operating Officer of Lucent Technologies.  In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent, where he helped lead the company through one of the most challenging periods in the telecom industry’s history and returned the company to profitability.

When Lucent was spun off from AT&T in 1996, Frank helped create the new company financially as the CRO of Lucent’s Network Systems Business and was a critical member of the team that met with investors around the world during Lucent’s initial public offering.  In 1999, he was appointed the Group President of Lucent’s Switching Solutions Business Unit, where he led Lucent’s multibillion-dollar, global Switching, Access and Application Software business.

Born and raised in New Jersey, Frank earned his MBA in Finance from St. John’s University and his bachelor's degree in accounting from St. Peter’s University. He started his career in 1979 at Bell Labs, holding a variety of financial, accounting and general management positions, and moved within AT&T, holding a series of position with increasing responsibility.

In 2005, 2006, and 2011 through 2021 Frank was ranked among America’s top CFOs by Institutional Investor magazine.

He currently serves on the Board of Directors of Humana, Inc., and is chair of the Audit Committee; Zoetis, Inc.; Hewlett Packard Enterprises; and is the Resident CFO at Deloitte University.